Introduction And Etiology

Antimalarial drug resistance represents the ability of a parasite strain to survive or multiply despite the administration and absorption of a drug given in recommended or higher doses, within the tolerance limits of the patient.
Clinical treatment failure differs from resistance, as failure may also result from vomiting, poor treatment adherence, substandard medicines, or incorrect dosing.
Resistance emerges due to genetic mutations in the parasite that either reduce drug binding affinity or increase drug efflux from the cell.
Mutant parasites undergo selection and propagate rapidly in the absence of combination therapy.

Epidemiology And Geographic Distribution

The Greater Mekong Subregion in Southeast Asia serves as the global epicenter for multidrug-resistant Plasmodium falciparum, including resistance to artemisinin derivatives and mefloquine.
In India, Plasmodium falciparum demonstrates widespread resistance to Chloroquine and Sulfadoxine-Pyrimethamine.
While Plasmodium vivax remains generally sensitive to Chloroquine in India, resistance is emerging, with anecdotal reports of delayed Artemisinin clearance originating from East India.
High resistance levels in North-Eastern Indian states mandate the use of specific Artemisinin-based Combination Therapy regimens distinct from the rest of the country.

Drug Class	Resistance Characteristics
Chloroquine	Resistance is widespread in P. falciparum globally and across India, rendering it obsolete as a first-line agent for this species. High prevalence of chloroquine-resistant P. vivax occurs in Indonesia and Papua New Guinea, with rare cases reported in India.
Sulfadoxine-Pyrimethamine	Widespread resistance led to its removal as monotherapy; it is strictly utilized in combination with Artesunate only in regions demonstrating preserved efficacy.
Mefloquine	Significant resistance poses a major problem along the Thailand-Cambodia and Thailand-Myanmar borders, restricting its use in these specific geographical areas.
Artemisinin	Resistance manifests strictly as delayed parasite clearance, where parasites remain detectable on day 3 of treatment, rather than complete treatment failure. Prevention of resistance absolutely mandates the use of Artemisinin-based Combination Therapy instead of monotherapy.

The standard first-line treatment across general regions of India consists of Artesunate administered for 3 days, combined with Sulfadoxine-Pyrimethamine for 1 day, supplemented by a single gametocidal dose of Primaquine on the second day.
In North-Eastern Indian states, the mandated first-line treatment is a co-formulated Artemether-Lumefantrine regimen administered over 3 days, alongside a single dose of Primaquine on the second day.
Alternative regimens reserved for travelers or second-line therapy include Atovaquone-Proguanil, Quinine combined with Doxycycline or Clindamycin, and Mefloquine.

Resistance requires suspicion if clinical symptoms worsen or parasite density fails to decrease following Chloroquine administration.
Recommended therapeutic options include Artemether-Lumefantrine, Atovaquone-Proguanil, or Quinine combined with Doxycycline or Clindamycin.
Anti-relapse therapy utilizing Primaquine for 14 days remains strictly required to eradicate hypnozoites.

Intravenous Artesunate serves as the definitive drug of choice for severe malaria, including resistant strains, owing to its rapid action and lower associated mortality compared to Quinine.
Parenteral therapy must transition to a full oral course of Artemisinin-based Combination Therapy once the patient regains the ability to tolerate oral medications to prevent recrudescence.

The National Vector Borne Disease Control Programme actively conducts Therapeutic Efficacy Studies at sentinel sites to track first-line antimalarial efficacy.
A documented treatment failure rate exceeding 10% strictly triggers a change in national drug policy.
Rational drug use mandates the absolute ban of oral artemisinin monotherapy in India to prevent further resistance development.
Strict clinical surveillance monitors for late treatment failure, defined as clinical recrudescence occurring within 28 days of initial treatment.